71.05
-0.42 (-0.59%)
| Previous Close | 71.47 |
| Open | 71.47 |
| Volume | 127,581 |
| Avg. Volume (3M) | 1,794,205 |
| Market Cap | 2,391,545,088 |
| Price / Earnings (TTM) | 66.40 |
| Price / Earnings (Forward) | 56.50 |
| Price / Sales | 6.81 |
| Price / Book | 12.63 |
| 52 Weeks Range | |
| Earnings Date | 28 Apr 2025 - 2 May 2025 |
| Profit Margin | 8.03% |
| Operating Margin (TTM) | 7.11% |
| Diluted EPS (TTM) | 1.07 |
| Quarterly Revenue Growth (YOY) | 49.80% |
| Quarterly Earnings Growth (YOY) | 70.10% |
| Total Debt/Equity (MRQ) | 226.72% |
| Current Ratio (MRQ) | 8.30 |
| Operating Cash Flow (TTM) | 48.80 M |
| Levered Free Cash Flow (TTM) | -102.77 M |
| Return on Assets (TTM) | 3.10% |
| Return on Equity (TTM) | 19.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | TransMedics Group, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 2.63 |
|
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.48% |
| % Held by Institutions | 115.50% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 105.00 (Piper Sandler, 47.79%) | Buy |
| Median | 104.50 (47.09%) | |
| Low | 104.00 (Canaccord Genuity, 46.39%) | Buy |
| Average | 104.50 (47.09%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 80.04 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 29 Apr 2025 | 105.00 (47.79%) | Buy | 92.43 |
| Canaccord Genuity | 11 Mar 2025 | 104.00 (46.39%) | Buy | 67.65 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |